In Segment C, participants will get ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Participants will acquire treatment until eventually illness progression or perhaps the contributors are unable to tolerate the study drugs. - "Our study uncovered the crucial purpose on the KLF16/MYC regulatory axis https://myleswhwhr.boyblogguide.com/31164805/brd4-targeted-therapy-abbv-744-clinical-data-no-further-a-mystery